sanofi-aventis pharmaceuticals news

sanofi-aventis will reduce its U.S. headcount by 400. The cuts will primarily come from its U.S. sales force, which had 5,700 employees prior to the move. sanofi-aventis will reduce promotional efforts for Ambien CR zolpidem for insomnia and Nasacort AQ triamcinolone acetonide for allergic rhinitis. The pharma also said it will outsource promotional activities for depression drug Aplenzin bupropion to a contract organization. sanofi-aventis has U.S. and Puerto Rican rights to market Aplenzin from Biovail Corp. (TSX:BVF; NYSE:BVF, Mississauga, Ontario). ...